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1. Introduction 
In most developed countries the problem of infertility has acquired not only medical and 
sociodemographic, but also economic significance. One of the key and vigorously 
developing trends in modern obstetrics is aimed at overcoming this problem and requires a 
multidisciplinary approach. The 2010 Nobel Prize was awarded to Robert Edwards, 85-year-
old British researcher and recognized the methods of assisted reproductive technologies 
(ARTs) which introduced a new era in human demography. ARTs are used to solve the 
problem of infertility; they use all treatment methods and procedures which support in vitro 
processing of human oocytes, sperm or embryos to become pregnant. These technologies 
involve in vitro fertilization (IVF) and transcervical embryo transfer, gamete intrafallopian 
transfer, zygote intrafallopian transfer, embryo intrafallopian transfer, gamete and embryo 
cryopreservation, oocyte and embryo donation, and surrogacy (Current Practices and 
Controversies in Assisted Reproduction. Report of.., 2001). 
25 July 1978 was marked by a significant event in the history of ARTs. On that day, the first 
"test tube baby" was born in an obstetrics and gynecology clinic located in Oldham, North 
West England. This was also the birth date of modern assisted reproduction. In Russia, the 
first baby born by this method was delivered in 1986 in the Research Center for Obstetrics, 
Gynecology and Perinatology, the division of the Russian Academy of Medical Sciences. 
Other leading centers in Russia are “Fertimed “Center for Reproduction and Genetics 
(Moscow), “ART-ECO” Clinic for Reproductive Health (Moscow), “ECO” Center for the 
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Treatment of Infertility, LLC (Moscow), International Center for Reproductive Medicine 
(Saint-Petersburg), the Baltic Institute of Human Reproductology (Saint-Petersburg), etc. 
2. In vitro fertilization and known reasons that reduce its efficacy 
In vitro fertilization of preovulatory oocytes and transfer of cleaving embryos into the 
patient's uterine cavity has become the prevalent method to overcome the problem of 
infertility (Pioneers in in vivo Fertilisation .., 1995). The IVF method was initially devised for 
those women whose Fallopian tubes were removed for one reason or another. However, at 
present, IVF is the most effective treatment for virtually all types of infertility, including 
endometriosis, polycystic ovary syndrome, oocyte donation (in infertile patients with 
oogenesis depletion), fertilization of an egg with a single sperm in cases of virtually absolute 
forms of male infertility (intracytoplasmic sperm injection - ICSI), carriage of an embryo by a 
voluntary egg recipient when a woman cannot carry the pregnancy due to some somatic or 
other diseases (Maheshwari et al., 2008). Despite all achievements, the IVF pregnancy rate is 
comparatively low. It ranges from 25% to 30% and has not changed considerably in recent 
years (Nyboe Andersen et al., 2009). This rate relates to a number of diverse factors that 
affect the reproductive process. Implantation failure following embryo transfer is the major 
problem in IVF (Bischof et al., 2006; Christiansen et al., 2006). IVF failures may be caused by 
a variety of factors: diminished ovarian reserve, maternal and paternal age, excessive body 
weight, endocrine disorders in the hypothalamus-pituitary-ovary system, as well as in the 
suprarenal and thyroid systems, diminished endometrial receptivity, quantity and quality of 
transferred embryos, number of transfers, and thrombophilic disorders.  
Ovarian reserve. Ovarian reserve is one of the factors that determine the efficacy of IVF 
(Gregory, 1998; Navot et al., 1987;  Scheffer et al., 2003). Assessing the ovarian reserve, 
specialists draw conclusions based on the prospects of ovarian stimulation in a particular 
patient. Conclusions may be used to define a specific procedure and further treatment 
prospects, as well as to make the right choice of the ovarian stimulation scheme and the 
quantity of drugs of human menopausal gonadotropin or follicle-stimulating hormone 
(FSH), which are necessary for an adequate response. The routine method for assessing the 
ovarian reserve measures basal FSH level on the 3rd or 4th day of the menstrual cycle and 
estimates the quantity of antral follicles with ultrasonography. However, at present, the 
prognostic significance of ultrasonography is considered less informative, even though it 
reflects the quantity and quality of oocytes (Damti et al., 2008). The role of new factors 
capable of reflecting the functional status of the ovary in a more precise manner is under 
discussion. (Gregory, 1998).  
Maternal and paternal age. Lintsen et al. (2007) concluded that the most important prognostic 
indicator to define the probability of pregnancy after IVF and ICSI is maternal age ( more 
frequently observed positive results -in 30-year-old women, less frequently - in women 
under 35, and least frequently - in women over 35). Physiological process of the gradual 
decline of ovarian function is one of the key obstacles for the efficacy of IVF, which depends 
on maternal age, current condition of the ovarian reserve and to a lesser extent on chosen 
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schemes of ovulation induction. The cases of women under 41 are treated as relatively 
promising, to reason the use of donated oocytes in older women (Maheshwari et al., 2008). 
Paternal age also affects the conception rate: it shrinks with men after 35 due to the quality 
of sperm to have been deteriorated by this age (Saleh et al., 2002).  
Excessive body weight. Menstrual dysfunction, polycystic ovary syndrome, hyperplastic 
processes in endometrium, infertility, miscarriage, gestoses, fetal hypotrophies, high rate of 
operative deliveries make up an incomplete list of reproductive disorders typical of obese 
women. 40% of women seeking for treatment of infertility in medical centers have excessive 
body weight; over 15% of such women are obese. The IVF program is preferable to start 
after the patient's body weight has become normalized; therefore, patients often fail to meet 
the required standards (Ku et al., 2006; Lintsen et al., 2005; Mc Clamrock, 2008; Megan et al., 
2008). Status of the hypothalamus-pituitary-ovary system, suprarenal and thyroid systems. 
Interaction of the two key pituitary hormones - FSH and luteinizing hormone (LH) - is 
essential for the adequate growth of follicles, as well as for the formation of viable oocytes. 
Studies of ovulation induction in hypogonadotropic patients showed that exogenous FSH 
stimulates the growth of follicles up to the preovulatory stage and its synthesis primarily 
depends on LH, i.e. adequate maturation of follicles takes place due to this gonadotropin. 
Insufficient concentration of LH disturbs paracrine mechanisms regulating granulosa cells, 
as well as endometrial proliferation, and results in inadequate luteal phase (Alviggi et al., 
2009; Balasch et al., 1995; Hull et al., 1994). Excessive concentration of LH also negatively 
affects the growth of follicles to be the result of suppressed aromatase activity, accompanied 
by fertilization disorders, decreased pregnancy rate decrease and increased miscarriage rate 
(Hillier, 1994). Thus, the threshold concentration (1-10 IU/l) is optimal for adequate 
folliculogenesis (Howles et al., 2006). It has been noted that low estradiol level in the blood 
serum (<200 pmole/l) on the 3rd day of the patient's menstrual cycle is a positive prognostic 
indicator of successful implantation in the IVF cycle. At the same time, some reports state 
that basal estradiol level was not a significant indicator of ovarian response to stimulation 
and did not correlate with the IVF result (Friedler et al., 2005). In recent years, researchers 
and clinicists have given a lot of consideration to the problem of thyroid gland dysfunction 
in infertile women (Bellver et al., 2008). Female reproductive system consists of interrelated 
structural elements: hypothalamus, pituitary gland, ovaries, other endocrine glands and 
target organs facilitating reproductive function. Thyroid gland is a chief part of the 
neuroendocrinal system; it significantly affects reproductive function. The hypothalamus-
pituitary-gonadal and hypothalamus-pituitary-thyroid systems are closely related due to 
the presence of common central regulating mechanisms. For example, the spread of thyroid 
gland dysfunction diagnosed at the examination in women, who seek clinical diagnosis and 
treatment of infertility, ranges from 2.5 to 38.3% (Lazarus & Premawardhana, 2005). In 
addition to gonadotropic hormones, ovarian function is determined by adrenal hormones 
produced under impact of ACTH. When a patient has developed any genetic defects in the 
enzyme systems, cortisol synthesis in adrenal glands decreases with the increase of level of 
ACTH followed by the increased production of androgens under normal synthesis. This 
condition may be typical of congenital adrenal hyperplasia. As a result of adrenal 
 Enhancing Success of Assisted Reproduction 80 
hyperandrogenism, the suppression of ovarian function takes place, which leads to the 
development of a number of disorders in the menstrual cycle accompanied by anovulation.  
Diminished endometrial receptivity. After high-quality embryos have been transferred into the 
uterine cavity and all evident causes for the failure of the IVF program have been 
eliminated, the unsuccessful IVF cycle is regarded as a result of disorders that occurred 
during the embryo implantation stage. A few years ago a new term - "repeated implantation 
failure" - was introduced (Margalioth et al., 2006; Tan et al., 2005). Recent years have shown 
that, despite the selection of obviously normal embryos for the transfer, only 20% of human 
embryos transferred in IVF cycles have been implanted in the uterus (International 
Committee for Monitoring Assisted Reproductive Technology (ICMART), 2002; Nyboe 
Andersen et al., 2009). This condition is considered to be based on the endometrial 
dysfunction occurring on the mollecular-cellular level. Lately, as a result of the tendency to 
transfer one or two embryos inside of an uterus, the method to determine repeated 
implantation failure has been modified. Margalioth et al. (2006) concluded that detailed 
examination should be done after 3 unsuccessful IVF cycles. Thus, the main causes are the 
factors which diminish endometrial receptivity: anatomical defects in the uterus, chronic 
endometritis, non-correspondence between the endometrial thickness and the day of 
embryo transfer, combined gynecologic pathology (adenomyosis, uterine fibroid), somatic 
diseases (including autoimmune diseases), and thrombophilias (Margalioth et al., 2006; Tan 
et al., 2005).  
Quantity of transferred embryos. Due to the absence of conventional clinical guidelines for the 
treatment of infertility with the IVF method, there are on-going discussions regarding the 
elective transfer of one embryo to patients under 40. In 2009, a mathematical model was 
drawn to prove that the transfer of only one embryo shall decrease the pregnancy rate by 
20% (Gelbaya et al., 2009). 
Embryo transfer on the stages of cleavage or blastocyst. The data obtained during the systematic 
review and meta-analysis (Papanikolaou et al., 2008) of 1654 patients (blastocyst transferred 
to 815 patients, cleaving embryo transferred to 839 patients) showed that live birth rate was 
higher with embryos transferred on the blastocyst stage as compared to the rate at the 
cleavage stage. Multiple gestation rates were the same for both study groups.  
3. Data on the IVF results as affected by pathologies of hemostasis 
As we have already noted, unsuccessful IVF cycles are caused by many factors, including 
thrombogenicity of the medical technology itself due to the high estrogen-gestagen rate and 
frequent presence of thrombogenic risk factors and predisposition to intravascular 
coagulation (thrombophilia) in women that need IVF. According to up-to-date conceptions, 
the term "thrombophilia" means predisposition to arterial or venous thrombosis as a result 
of several hereditary or acquired disorders in the systems of blood coagulation, 
anticoagulation, or fibrinolysis (Bates et al., 2008;  Heit, 2007). We use this term in a different 
sense, which makes most of the described thrombophilias no more than thrombogenic risk 
factors that may or may not become evident during the lifespan of a human being. 
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According to our conceptions, thrombophilia should be detected in case of everpresent 
thrombosis risk factors (thromboses) or miscarriage syndrome in the individual medical 
history. In order to prove it, we note the fact that, according to the guidelines of the 
International Society on Thrombosis and Haemostasis (ISTH), diagnosis of antiphospholipid 
syndrome (APS) shall be considered invalid unless at least one or more clinical implications 
of this pathology match the results of special laboratory assays (lupus anticoagulant effects, 
antiphospholipid antibodies in the diagnostic titer) (Harris & Pierangeli, 2008). 
Some publications indicate data on typical changes in the system of hemostasis that occurs 
during the IVF cycle. In particular, demonstration has shown that hormonal stimulation of 
the ovaries is accompanied by the increased von Willebrand factor, factors V and VIII, 
fibrinogen, enhanced APC resistance, and the decreased activity of principal physiological 
anticoagulants - antithrombin, proteins C and S (Andersson, 1997; Biron et al., 1997; Chan & 
Dixon, 2008; Curvers et al., 2001b; Nelson, 2009). Relationship between the predisposition to 
intravascular coagulation (thrombophilia) and unsuccessful ART results is actively 
discussed in current publications; however, mechanisms to produce the impact that 
increases thrombotic readiness on IVF are not absolutely clear. It is reported that women 
with thrombophilia may have increased risks for spontaneous abortion, preclinical 
pregnancy loss and recurrent implantation failure (Christiansen et al., 2006; Coulam et al., 
2006b; Curnow et al., 2006; Many et al., 2001; Seghatchian et al., 1996; Stern & Chamley, 
2006; Urman et al., 2005; Wichers et al., 2009; Younis et al., 2000). Presently, most studied 
and prevalent thrombophilias include APS and such risk factors as hereditary antithrombin 
III deficiency, factor V Leiden mutation, prothrombin mutation, polymorphism of 
methylenetetrahydrofolate reductase (MTHFR) gene, plasminogen activator inhibitor-1 
(PAI-1), fibrinogen, platelet glycoproteins ITGA2, ITGB3, and some others. Beer and Kwak 
(2000) treated unsuccessful IVF programs as the evident indication for assays capable of 
detecting hereditary and acquired thrombophilias. In 2004, Azem et al. (2004) demonstrated 
higher occurrence of hereditary thrombophilia in women with multiple IVF failures as 
compared to the group of fertile women who became pregnant after the first IVF cycle. In 
the research conducted by Qublan et al. (2006), 69% of women with recurrent IVF failures 
had at least one hereditary or acquired thrombogenic risk factor as compared to 25% of 
women in the group where this reproductive technology was successful. In the publication 
presented by Grandone et al. (2001), factor V Leiden mutation prevailed (14.4%) in women 
with recurrent IVF failures as compared to the controls (1%). Recently, Coulam and 
Jeyendran (2009b) have shown that frequency of genetic polymorphisms has been 1.6 times 
higher in infertile women with IVF failures as compared to the fertile group; thus, 
polymorphism of the MTHFR gene has prevailed. It has been also noted that the connection 
of thrombogenic risk factors with recurrent miscarriages and repeated implantation failures 
after IVF is mainly evident in the simultaneous carriage of several thrombogenic mutations 
and polymorphisms (Coulam et al., 2006b).  
Mechanisms of hemostasis and implantation pathologies typical of some thrombophilias 
(carriage of thrombogenic risk factors): 
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- factor V Leiden mutation (1691G>A). As long as activated protein C (APC) blocks 
activated factor V in regular conditions, resistance of the latter to APC can cause the 
increase of thrombinemia (Bertina et al., 1994; Dahlbäck et al., 1993). It is considered 
that patients who experience this mutation have higher risks for thrombosis and 
subsequent pregnancy loss. (Ridker et al., 1998; Urman et al., 2005; Younis et al., 2000); 
- prothrombin mutation (20210G>A). This mutation is accompanied by the increased 
synthesis of prothrombin in the liver and increased risk for venous thrombosis 
(Girolami & Vianello, 2000; Poort et al., 1996); 
- MTHFR gene polymorphism (C677>T) potentially causes increase in the level of 
homocysteine in blood (> 15 μmole/l), which affects human reproductive function 
(Nelen et al., 1998). In their publication Berker et al. (2009), interconnection between 
high level of homocysteine in the follicular fluid and decreased quality of oocytes and 
embryos in IVF programs has been discovered. High level of homocysteine in blood 
plasma relates to the decreased diameter of blood vessels located in the chorionic villi 
and miscarriage (Jerzak et al., 2003; Nelenet al., 2000). Thrombogenic action of 
homocysteine is based on the damage of endothelial cells, inhibition of prostacyclin 
synthesis, and increased platelet aggregation; 
- PAI-1 gene polymorphism (5G>4G; 4G/4G) is related to the increased expression of PAI-
1 in the blood plasma and endometrium, which disturbs the reaction of plasminogen 
activation into plasmin (Anteby et al., 2004; Buchholz et al., 2003; Ebish IM,  et al., 2008; 
Kim et al., 1997); 
- antiphospholipid syndrome. Damaging effect of antiphospholipid antibodies (APLAs) 
on oocytes and embryos on the early development stages has been indicated 
(Matsubayashi et al., 2006). Women with APS demonstrate high level of NK cells in the 
peripheral blood and endometrium. It is possible that disturbed synthesis of mediator 
molecules which participate in embryo adhesion and invasion by NK cells is one of the 
causes of disturbed signaling interaction between the blastocyst and endometrium on 
the earliest implantation stages (Quenby et al., 2009; Sher et al., 2000). APLAs stimulate 
PAI-1 synthesis that may cause disturbed degradation of intercellular matrix and 
decreased depth of blastocyst invasion. 
Thus, making a brief summary, different forms of thrombophilia refer to different 
pathogenesis of implantation failures. Fixed and common conception for all thrombophilias 
is that pathology mechanisms are revealed in the earliest stages of pregnancy and are 
caused due to microcirculation and hemostasis disorders, as well as vessel wall pathology. 
Some researchers deny the impact of mutations of certain genes within the hemostasis 
system or isolated asymptomatic increase in the level of phospholipid antibodies on 
implantation. However, combination of several factors is believed to considerably increase 
individual risk of possible implantation failures and miscarriage. While estimating the 
occurrence of APS and mutations of genes participating in the hemostasis system in infertile 
women and women with IVF failures, specialists actively investigate qualitative changes on 
the level of endometrial structures and vascular endothelium accompanied by 
thrompophilia (Anteby et al., 2004; Coulam & Roussev, 2009a). Local mechanisms in the 
basis for implantation failures which occur along with thrombophilias are under 
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investigated. Excessive activation of coagulation, imbalance in the coagulation system, 
endotheliopathy, local haemorrhages and microthrombi in the area of blastocyst invasion 
are common elements in the mechanism of implantation failures caused by thrombophilias. 
Thus, different forms of thrombophilia result in disorders on different stages of the 
coagulation cascade and fibrinolysis.  
Analysis of publications demonstrates diverse expert opinions on the role of some 
mutations, polymorphisms of genes which are part of the hemostasis system and APS role 
in the development of infertility and ART failures. The American Society of Reproductive 
Medcine does not find it necessary to examine women who participate in IVF programs in 
order to detect risk factors for thrombophilia (American Society of Reproductive Medcine .., 
2008). On the contrary, approach of the American Society for Reproductive Immunology to 
treat the same problem is completely opposite (American Society for Reproductive 
Immunology Antiphospholipid Antibody Committee .., 2000; Gleicher et al., 2002). 
Inconsistency of the opinions mentioned above may be explained by the absence of vast 
multicentral studies, use of diverse methodological approaches to diagnosing hemostasis 
pathologies and interpretation of examination results.  
We believe that the most perspective approach in this area may be found in simultaneous 
consideration of thrombogenic risk factors and monitoring of the results collected with 
"global" methods which are capable of detecting disorders in the natural balance of pro- and 
anticoadulants in blood plasma under controlled ovarian hyperstimulation. This approach 
offers specialists the potential for the thrombin generation assay (TGA). This assay is known 
to define the dynamics and intensity of thrombin development; thrombin is the key 
hemostatic enzyme and relates to the group of integral indexes of the coagulation system 
(Hemker et al., 2000; Hemker et al., 2003; Hemker et al., 2006; Regnault et al., 2003; Wielders 
et al., 1997). This methodological approach has been successfully tested as a part of the 
complex estimation of the hemostasis system during pregnancy (Dargaud et al., 2010), 
preeclampsia (Macey et al., 2010) and oral contraceptive intake (Tchaikovski et al., 2007). 
Recent publication presented interesting data on the specifics of thrombin generation in  
blood plasma within IVF cycle (Westerlund et al., 2012). Shifts detected in 31 women were 
interpreted as the result of estrogen load and ovarian hyperstimulation syndrome and 
estimated to be vital for thrombosis prediction and IVF monitoring. 
Besides, a number of researchers raise a great interest in the decrease of fibrinolytic blood 
activity, which is often detected in recurrent miscarriages, APS, deep vein thrombosis of 
lower extremities, oral contraceptive intake, myocardial infarction, and malignant 
neoplasms (Bertina, 1997; Birkenfeld et al., 1994; Curnow et al., 2006;  Dmowski et al., 1995; 
Egbase et al., 1999; Lisman et al., 2005;  Meltzer et al., 2009; Meltzer et al., 2010; Triplett, 
1989; Wichers et al., 2009). The system of fibrinolysis, as well as the system of coagulation, is 
a complex system which gives characteristics to fibrinolytic responses and its central 
element that plays role in the activation of plasminogen into plasmin. Lately, its pathologies 
have been treated as new approach that explains the mechanisms of thrombosis 
pathogenesis (Zorio et al., 2008). The analysis of the fibrinolysis system during the IVF 
procedure shows the decrease in fibrinolytic responses due to several reasons (Andersson et 
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al., 1997; Aune et al., 1991; Kim et al., 1981; Many et al., 2001; Martinez-Zamora et al., 2011; 
Meltzer et al., 2010; Nelson, 2009; Rice et al., 1993; Sarto et al., 2000). One of them is a decreased 
activity of tissue plasminogen activator (t-PA), increased level of its inhibitor - plasminogen 
activator inhibitor-1 (PAI-1), and increased level of thrombin-activatable fibrinolysis inhibitor 
(TAFI) dependent on the response of vascular endothelium (Bouma & Meijers, 2003; Martınez-
Zamora et al., 2010; Martinez-Zamora et al., 2011; Meltzer et al., 2010).  
4. Potential methods for the correction of hemostasis and fibrinolysis 
pathologies within the IVF program 
Analysis of publications shows that correction of imbalanced homeostatic and fibrinolytic 
responses may be used in case of hormonal load within the IVF program accompanied by 
thrombophiia or present thrombogenic risk factors in a patient (Martinez-Zamora et al., 
2011; Nelson & Greer, 2008; Rova et al., 2012; Urman et al.,  2005). This is reasonable to 
determine thrombotic readiness, which becomes evident through the increase of general 
coagulation activity and thrombinemia and/or fibrinolysis suppression identified, for 
example, with the help of the thrombin generation assay upon detecting markers of 
thrombinemia and estimating fibrin clot lysis time for the fibrin obtained from euglobulins 
(Lisman et al., 2005; Wichers et al., 2009).  
The use of heparins may become one of the methodologies aimed at the decrease of 
thrombogenicity and increase of IVF efficacy (Nelson & Greer, 2008; Urman et al., 2009). 
Still, there are no clear indications for the selection of women that need heparin prophylaxis 
within the IVF cycle.  
Correction of hypofibrinolysis within IVF cycle also offers some difficulties for there are no 
published evidence of any successful drug therapy. Moreover, the hypothetic possibility to 
use pharmaceutical drugs - fibrinolysis activators (streptokinase, urokinase, and tissue 
plasminogen activator) - cannot be considered due to the absence of acute thrombosis. In the 
study conducted by Bjornsson et al. (1989), regular intake of aspirin in high doses (650 mg 
every 12 hours) caused the acceleration of fibrinolysis. But the mechanism of this effect is 
not absolutely clear, whereas the use of acetylsalicylic acid in high doses is unsafe due to the 
potential ulcerogenic effect. Nevertheless, it has been known for about 50 years that some 
stimuli (venous occlusion, physical load, desmopressin) lead to the acceleration of 
fibrinolytic responses facilitated by the fast increase of t-PA in blood due to its enhanced 
secretion by vascular endothelium. The effects of intermittent pneumatic compression (IPC) 
used to decrease the occurrence of postoperative venous thrombosis became our 
interests(Browse et al., 1977; Jacobs et al., 1996; Januszko et al., 1967; Holemans, 1963; Keber 
et al., 1979;  Tarnay et al., 1980; Turpie et al., 1977; Weitz et al., 1986). Macdonald et al. (2003) 
published the results of their randomized pilot study demonstrating the efficacy of heparin 
prophylaxis combined with IPC in the course of neurosurgical invasions. The study 
conducted by Tarney et al. (1980) showed that intermittent compression of the calf, along 
with the increase in linear blood velocity and the decrease in venous stasis, increases local 
and systemic fibrinolytic potential (according to the shortened fibrin clot lysis time) in 
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patients with acute myocardial infarction and prolonged movement disorders. Thus, the 
larger the volume of the compressed tissue gets, the more apparent became the response. 
The increase in blood and t-PA fibrinolytic activity after mechanical exposure on blood 
vessels is supported by the results presented by many authors (Bjornsson et al., 1989; 
Christen et al., 1997; Jacobs et al., 1996; Pandolfi et al.,1968; Salzman et al., 1987; Tarnay et 
al., 1980). However, we were not able to find any published data on the dynamics of PAI-1 
activity. In the meantime, the correlation of the activities presented by these participants of 
the fibrinolysis system determines its overall efficacy. Some publications relate the 
mechanism of the IPC antithrombotic effect to the inhibition of coagulation cascade due to 
the expression of the tissue factor pathway inhibitor (TFPI) into  blood flow and the 
decrease in the level of factor VIIa (Chouhan et al., 1999; Christen et al., 1997). Currently IPC 
is used worldwide for thromboprophylaxis in patients with strokes, after arthroplasty and a 
number of other operative invasions, in medical emergency,and applicable, firstly, in cases 
when administration of anticoagulants is dangerous due to the development of 
haemorrhage (Geerts & Selby, 2003; Gordon et al., 2012). As a rule, IPC is performed on the 
lower extremities, though some publications present positive results for the upper 
extremities compression (Knight & Dawson, 1976). Despite the fact that legs weigh more 
than arms, it was proved that forearm veins have considerably more t-PA than leg veins 
(Pandolfi et al., 1968). In our study this form of IPC was used to activate fibrinolytic 
responses within the IVF program and in the presence of relevant indications.  
5. Оriginal researches 
This publication is based on the clinical study carried out to define the role of pathologies in 
the coagulation and fibrinolysis systems facilitating IVF failures, as well as to estimate the 
results of their correction. 
In the framework of prospective analysis we collected data on 327 women who have been 
visiting the Center for Saving and Recovering the Reproductive Function, a subdivision of 
the Clinical Regional Hospital (Barnaul), from 2010 to 2012, to participate in the IVF 
program due to infertility. This study was approved by the Regional Ethics Committee of 
the Altai Medical University, and all the participants under study expressed their informed 
consent.  
At the first visit women were interviewed about their obstetric, gynecological, and 
thrombotic history, possible diabetes, pathologies in the thyroid gland, heart and blood 
vessels. We have conducted ultrasonography of the genitals in order to detect organic 
pathologies of the pelvic organs and estimate the ovarian reserve (according to the quantity 
of antral follicles), aspiration biopsy and histologic examination of the endometrium, as well 
as to detect infections, including sexually transmitted diseases. We have also conducted 
general and special laboratory assays, including hormone panel assessment, blood 
chemistry panel, thrombogenic mutation and polymorphism carriage, coagulation profiles, 
and homocysteine presence. Then, based on the obtained results, women received 
professional consultation by obstetrician-gynecologists, physicians, and hematologists. 
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The study was chronologically conducted in two stages. At the first (observational) stage, 
we examined a random sampling of 163 women in their IVF cycle. At the second stage, we 
examined a random sampling of 164 women, 98 of which underwent the correction of the 
hemostasis and fibrinolysis systems in the presence of relevant indications - increased 
thrombin generation and/or decreased fibrinolytic activity of  blood plasma (controlled 
group or group with the therapeutic effect on hemostasis and fibrinolysis) (Fig. 1).  
 
Figure 1. Division of women participating in the study into groups and subgroups 
The selection criterion for the patients was any form of infertility non-responsive to 
traditional treatment. The exclusion criteria were somatic diseases serving as 
contraindications for carrying a pregnancy and delivery, congenital malformations or 
acquired deformations of the uterine cavity that make embryo implantation or carrying of a 
pregnancy impossible, ovarian tumors, benign uterine tumors that require operative 
invasion, malignant neoplasms. 
All patients are representatives of the Caucasian race, their age ranged from 21 to 42 years 
(Table 1) 
There was a difference in clinical profiles of women representing the two groups. The 
second group of patients suffers from chronic endometritis and has lower ovarian reserve. 
Besides, male infertility factor was more frequent in this group. 
We used standard protocols to induce superovulation. In 72.4% (237 patients) of the whole 
population we used the "prolonged" protocol with diphereline (Ipsen) 0.1 mg or decapeptyl 
(Ferring) 0.1 mg and gonadotropic preparations - puregon (MSD) 150-250 IU, menopur 
(Ferring) 225 IU, or gonal (Merck Serono) 225 IU. In 27.6% (90 patients) of the whole 
population we stimulated superovulation using the same gonadotropic preparations and an 
antagonist - cetrotide (Merck Serono) 0.25 mg. Transvaginal follicle puncture was conducted 
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with ultrosonic guidance using Medison Sonoace X8 machine. After we counted obtained 
oocytes and estimated their quality with the conventional scale (normal oocytes of good 
quality - 4-5 points, modified oocytes - less than 4 points), oocytes and embryos were 
cultivated in 6-well plates in the IVF medium (Vitrolife, Sweden), at 37 degrees Centigrade, in 
humid atmosphere containing 5% of CO2. Sperm processing was conducted with the Sil-Select 
Plus medium (FertiPro, Belgium). The ICSI procedure consisted of fertilization with the 
injection of a single sperm into the oocyte (177 married couples) in case of decreased sperm 
mobility or irregular sperm morphology. Embryo transfer was conducted with ultrasonic 
guidance on the 3rd day of cultivation. Embryos with the highest quality rating (A, AB) were 
selected for the transfer. Pregnancy was diagnosed two weeks after the embryo transfer by 
means of detecting b-human chorionic gonadotropin (b-hCG). After three weeks we defined 
quantity and location of the implanted embryos with ultrasonography (in 124 patients).  
 
Indication Total 
(n=327) 
Group 1 
(n=163) 
Group 2 
(n=164) 
P-value* 
Age, years (mean ± SD) 33.7 ± 4.1 33.2 ±3.6 34.4 ± 3.9 > 0.5 
BMI > 25 kg/m2, n (%) 61 (18.7) 34 (20.9) 27 (16.5) 0.323 
Genital pathology: 
- Chronic endometritis, n (%) 108 (33.0) 42 (25.8) 66 (40.2) 0.006 
- Endometriosis, n (%) 55 (16.8) 28 (17.2) 27 (16.5) 0.883 
- Myoma, n (%) 45 (13.8) 25 (15.3) 20 (12.2) 0.426 
IVF failure registered in the 
history, n (%) 
36 (11.0) 19 (11.7) 17 (10.4) 0.727 
Low ovarian reserve, n (%) 55 (16.8) 19 (11.7) 36 (21.9) 0.017 
Extragenital pathology: 
- Hypothyroidism, n (%) 49 (15.0) 21 (12.9) 28 (17.1) 0.352 
- Arterial hypertension, n (%) 6 (1.8) 2 (1.2) 4 (2.4) 0.684 
Infertility causes: 
- Tubal factor, n (%) 119 (36.4) 61 (37.4) 58 (35.4) 0.730 
- Male factor, n (%) 138 (42.2) 59 (36.2) 79 (48.2) 0.033 
- Endocrinal factor, n (%) 29 (8.9) 14 (8.6) 16 (9.8) 0.848 
Combination of female and 
male factors, n (%) 
41 (12.5) 23 (14.1) 17 (10.7) 0.316 
P-value* for within-group comparison (Fisher,s exact test); SD, standart deviation 
Table 1. Clinical characteristic of the patients examined in the IVF cycle. 
Technique of laboratory assays for hemostatic and fibrinolytic profiles. 
Examination was conducted three times: 1-2 days before the start of controlled ovarian 
hyperstimulation and an IVF program (1st observation point), 2-3 days before the puncture 
of ovarian follicles (2nd observation point), and on the 12th-14th day after the embryo 
transfer (3rd observation point), when the outcome in terms of pregnancy was defined by 
estimating the level of b-hCG. 
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Sampling of venous blood was in the cubital vein in VACUETTE test tubes with the buffer 
solution of sodium citrate with the proportion of 9:1 (9NC Coagulation sodium citrate 3.2%). 
Blood was centrifuged at 1400 g and room temperature for 15 minutes. Plasma samples 
were generally studied within the two hours after being obtained. Prior to conducting 
immune-enzyme assays and estimating the endogenous thrombin potential, plasma was 
stored at -40 degrees Centigrade for the period of time ranging from 24 hours to 1 month. 
Measuring of the endogenous thrombin potential was made as a part of the thrombin generation 
assay (TGA). We believe that this method may be regarded as a historical modification of 
the two-stage self-coagulogram suggested by Berkarda et al. (1965) and developed to pursue 
similar goals. It was demonstrated that TGA allows experts to measure the dynamics of 
thrombin generation and inactivation with high precision (Hemker et al., 2003; Hemker et 
al., 2006). To perform calibrated automated thrombography, the Fluoroskan Ascent 
microplate fluorometer was applied (Thermo Fisher Scientific, Finland) equiped with a 
dispenser with Thrombinoscope 3.0.0.26 software. Coagulation of plasma under study was 
conducted in the presence of tissue factor (5 μM) and phospholipids (4 μM); thrombin 
generation was continually registered by measuring the signal of fluorogenic substrate (Z-
Gly-Gly-Arg-АМС). The following parameters were considered: endogenous thrombin 
potential (ETP, nM×min), calculating the area under the thrombin generation curve and 
taking into account specifics of the enzyme inactivation, and peak thrombin concentration - 
Peak thrombin (nM/l), maximal thrombin concentration per time unit. 
Activity of t-PA and PAI-1 was defined by means of the immune-enzyme analysis with sets of 
reagents t-PA Combi Actibind ELISA Kit and Actibind PAI-1 ELISA (Technoclone, Austria), 
while the collected data was estimated by mutual comparison. Due to the fact that these 
important participants of fibrinolytic responses are antagonistic to each other and have a 
common origin (vascular endothelium), we calculated the index of endothelial ability to 
activate fibrinolysis (EAAF index). To do that we applied the following formula: 
Activity of t PA,  un / ml
EAAF index,  %  100%.
Activity of PAI 1,  un / ml
   
Defining clot lysis time (CLT). Many authors refer this method to the group of global assays 
for fibrinolysis assessment. It can be conducted in a variety of ways (Lisman et al., 2005; 
Martinez-Zamora et al., 2011; Wichers et al., 2009).  
Method to define spontaneous lysis time of a fibrin clot obtained from plasma euglobulins 
was described by Kowarzyk and Buluk (1954). It is based on the precipitation of euglobulin 
fraction stabilized with sodium citrate in the acid medium with the simultaneous removal of 
fibrinolysis inhibitors. Then, following this methodology, specialists promote clot formation 
by recalcifying the reconstituted euglobulin solution and register period for its complete 
dissolution at fixed temperature (+37 degrees Centigrade). Martinez-Zamora et al. (2011) have 
recently published original CLT results obtained in women participating in IVF cycles using 
another method described by Lisman et al. (2002). In particular, this method implies the 
study of CLT for clots obtained from blood plasma by means of activitaing fibrinolysis with 
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exogenous t-PA. For our study we use a modified method suggested by Kowarzyk and 
Buluk (1954) and used kaolin that activates the contact phase of coagulation and starts 
activation cascade. Factor XIIa → kallikrein → plasmin. Description of this method was given 
earlier by Barkagan and Momot [Barkagan Z.S., Momot A.P. Diagnosis and controlled 
therapy of hemostasis pathologies. / M., Publisher: Nyudiamed-AO, 2001. - 296 P.]. Range of 
normal CLT variations in this modification is 8-12 minutes. 
Definition of the D-dimer concentration in blood plasma was conducted with the help of reagent 
set D-dimer Red-700 (Helena Bioscience, UK) and blood coagulation analyzer Sysmex CA-
1500 (Sysmex, Japan). This parameter was considered in accordance with conventional 
conceptions as a global marker for the completion of fibrin generation and fibrinolysis of 
stabilized fibrin.  
Definition of gene mutations and polymorphisms, predisposing to thrombosis, was conducted 
with the method of polymerase chain reaction. Thus, we detected the carriers of factor V 
Leiden (1691G>A) and factor II (20210G>A) mutations, MTHFR (C677>T) and PAI-1 gene 
polymorphisms related to potential activation of coagulation or decreased plasmin 
generation, as well as to IVF failures and miscarriages (Coulam et al., 2006a).  
5.1. Statistical analysis 
Statistical processing of the obtained data was made with the following software: Microsoft 
Office Excel 2003, Statistica 6.1, and Medcalc 12.2.1. Validity of the differences in mean 
values was defined with the Student's t-test (t). Group distribution normalcy was estimated 
with the Shapiro-Wilk test. In cases when the distribution deviated from the norm, we used 
the non-parametric Mann-Whitney U test for two independent groups and the Spearman's 
rank correlation coefficient (R). For experimental data presented in percentages or rates the 
Fisher's exact test was used. Odds ratio (OR) and log-linear rate analysis were calculated as a 
measure of predictor impact. To estimate the accuracy of obtained values, we defined a 95% 
confidence interval. Differences P<0.05 were considered statistically significant. We assessed 
the efficacy of the chosen treatment methods with conventional criteria applied in evidence-
based medicine, including Absolute Risk Reduction (ARR), Relative Risk (RR), Relative Risk 
Reduction (RRR), Number Needed to Treat (NNT), and Confidence Interval (CI). 
5.2. Study results 
5.2.1. Estimation of hemostatic and fibrinolytic indications in the IVF cycle and definition 
of threshold values occurring in the assay results for the selection of women who need 
therapeutic intervention during the controlled ovarian hyperstimulation 
At the beginning of the study, it was important to investigate shifts in the hemostatic and 
fibrinolytic systems that may affect IVF outcomes (in terms of the pregnancy rate) and to 
define their quantitative level that may help in selecting those women who need the 
correction of disturbed hemostatic and fibrinolytic responses. As a result, we defined that 
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thrombin generation in the observational group had considerably increased after the start of 
controlled ovarian hyperstimulation in response to a sharp increase in the level of estrogens 
in blood, which is consistent with recently published data (Westerlund et al., 2012). We have 
also found that the degree of the increase in thrombin generation is different at successful 
and unsuccessful IVF outcomes (Table 2). In particular, the values of such thrombin 
generation factors as ETP and peak thrombin concentration at the 2nd observation point 
were higher in case of IVF failures (P<0.001) as compared with the similar data in patients 
with pregnancies. 
 
Indication At IVF failure (n=107) At pregnancy (n=56) 
1st 
observation 
point 
2nd 
observation 
point 
3rd 
observation 
point 
1st 
observation 
point 
2nd 
observation 
point 
3rd 
observation 
point 
ETP, nМ/min 1655±39.2** 2060.5±52.7** 1853.9±55.6** 1574.8±36.9 1723±54.2 1632.7±56.4 
Peak 
thrombin 
concentration, 
nM/l 
328.6±24.8** 394.1±25.6** 378.4±25.5** 313.2±24.6 338.3±25.5 310.1±26.0 
t-PA, activity, 
un/ml 
0.36±0.16 0.37±0.18 0.38±0.18 0.37±0.14 0.36±0.16 0.35±0.17 
PAI-1, 
activity, 
un/ml 
4.22±2.98 4.08±2.76 4.10±2.16 3.67±2.68 3.41±2.87 3.25±2.31 
EAAF index, 
% 
8.5±3.4 9.1±4.1 9.3±4.2 10.0±4.1 10.5±4.9 10.7±4.6 
Clot lysis 
time, min 
13.5±3.7* 14.3±3.9* 14.9±3.8* 11.2±3.5 11.9±2.9 12.5±3.3 
D-dimers, 
ng/ml 
223.7±31.7** 266.4±27.8* 321.0±31.4** 198.5±25.4 251.6±26.1 298.4±28.4 
t – test; * - in this table, as well as in tables 5, 8-11, the validity of differences P<0.05 between the groups characterized 
by different outcomes occurring within the same observation periods of the IVF cycle; ** - the same, P<0.01. 
Table 2. Quantitative level and change dynamics of hemostatic and fibrinolytic indications (mean ± SD) 
in women of the 1st (observational) group (n=163) 
The most significant adverse indication for this reproductive technology was ETP value, 
which range limits at different IVF outcomes in the middle of the cycle did not intersect 
even with the M ± 3SD limit (Fig. 2). Peack thrombin concentration also changed, but its 
values in the compared groups did not intersect within the M ± SD limit.  
With regard to the conducted studies, the threshold value for the positive decision on 
administering heparin prophylaxis was set according to the following criteria: ETP exceeds 
1900 nM/min and/or increased Peack thrombin concentration of over 360 nM/l.  
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Figure 2. Definition of the threshold values for TGA indications (ETP and peak thrombin 
concentration) at different IVF outcomes in the 1st (observational) group (at the 2nd observation point). 
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The level of D-dimers, a known marker for fibrin generation and fibrinolysis, showed less 
distinctive differences in subgroups 1.1 and 1.2, even though it was slightly decreased, 
according to the mean data, in case of IVF failures (Table 2). Mean values of this indication 
in virtually healthy women of fertile age registered in our Center were equal to 205.3 ng/ml, 
with М ± 2SD 148.5 - 262.1 ng/ml. Respectively, registered results of the D-dimer level at the 
2nd observation point were within the allowed value limits or slightly exceeded them. 
It was more difficult to define the threshold values that reflect the decrease in the activity of 
fibrinolytic responses and allow specialists to select patients in need of hypofibrinolysis 
correction. Recent important publications devoted to this field demonstrate that 
hypofibrinolysis may be typical of some women who participate in the IVF procedure, but 
this pathology is original and not triggered in the course of controlled hormonal stimulation 
as a part of the IVF program (Martinez-Zamora et al., 2011; Westerlund et al. 2012). We 
received similar data proving that the suppression of fibrinolytic responses was actually 
typical of a number of women before the beginning of the IVF cycle. Suppression was 
steady throughout the cycle. Dynamics analysis of the changes in t-PA and PAI-1 activities, 
their EAAF index, and clot lysis time revealed more dramatic shifts at IVF failures, though 
the difference between the mean values of the parameters under study turned out to be 
invalid (P<0.05) (Table 2). Nevertheless, we have recorded two facts. First, mean values of 
the EAAF index defined in the group of 10 virtually healthy female volunteers (20-23 years) 
were equal (М±SD) to 11.0±3.3%. Second, in case of IVF failures we registered decreased 
EAAF indexes (less than 11%) in 93.5% (43 out of 46) of women in the 1st (observational) 
group before the start of the IVF program (1st observational point) as compared to 4,1% (2 
out of 49) of women after successful impregnation (P<0.000001) (Table 3). 
We used the values of the applied CLT assay to be the method of general fibrinolysis 
monitoring and refused to consider it as a potential criterion for the selection of women in 
need of therapeutic invasion in relation to its laboratory standardization. Thus, to select 
females to undergo IPC procedure we chose EAAF index calculation rate, which records the 
correlation between t-PA and PAI-1 activities, with the value of less than 11%.  
Back to the data presented above and obtained during the study of the hemostasis and 
fibrinolysis systems in the patients of the 1st or observational group (n=163), one can see 
significant correlation between the detected pathologies and certain IVF outcomes (Table 3). 
Adverse shifts in these systems had records in 114 out of 163 women (70%) in the 1st group. 
In general, the IVF cycle efficacy at this stage of the study was equal to 34.4%, however, 
certain hemostatic and fibrinolytic pathologies facilitated the decrease in the number of 
successful impregnations from 95.9% (47 out of 49 women in subgroup 1.1) to 7.9% (9 out of 
114 women in subgroup 1.2), i.e. in 12.1 times (P<0,000001).  
5.2.2. Results of the therapeutic invasion in the hemostatic and fibrinolytic systems 
administered for the increase in the number of successful IVF outcomes 
Correction of the hemostatic system at the excessive thrombin generation initially arranged 
the administration of heparin prophylaxis by means of subcutaneous introduction of 
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nadroparin calcium (Sanofi-Aventis): 0.3 ml twice a day for 12-14 days. Decision to begin the 
therapy was based on marking a suprathreshold increase in the major indications of 
thrombin generation - ETP (over 1900 nM/min) and/or Peack thrombin concentration (over 
360 nM/l) at the 2nd observation point. 
 
Patient subgroups 
Аbs. 
(n=163) 
% of the 
whole 
study 
populatio
n 
Impregnation 
Аbs. 
(n=56) 
% of 
pregnant 
women 
1.1. Without target indicators 
of hemostatic and fibrinolytic 
pathologies  
49 30.1 47 83.9 
1.2. With hemostatic and 
fibrinolytic pathologies 
114 69.9 9 16.1 
1.2.1. With ETP exceeding 1900 
nM/min and/or increased 
Peack thrombin concentration 
of over 360 nM/l (at the 2nd 
observational point)  
46 28.2 3 5.4 
1.2.2. With decreased EAAF 
index of less than 11% and 
prolonged clot lysis time of 
over 12 min. (at the 1st 
observational point) 
35 21.5 4 7.1 
1.2.3. With ETP exceeding 1900 
nM/min and/or increased 
Peack thrombin concentration 
of over 360 nM/l (at the 2nd 
observational point) and 
decreased EAAF index of less 
than 11% (at the 1st 
observational point) 
33 20.2 2 3.6 
Table 3. IVF results in women of the 1st (observational) group depending on the presence or absence of 
hemostatic and fibrinolytic pathologies 
Impact on the vessel wall to increase fibrinolytic activity was made by means of IPC. In the 
publication byKakkos et al. (2005) a comparative description of the two widely used 
compression machines - SCD Express™ Compression System (Tyco Healthcare Group LP, 
Mansfield, MA, USA) was introduced with a rapid inflation device that delivers uniform 
compression and VenaFlow® (Aircast Inc, Summit, NJ, USA). However neither of them is 
normally equipped with proper braces to provide mechanical invasion for arm vessels. Still, 
we found it important to compress this vessel area to exclude even the hypothetic possibilty  
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Subgroups examined Аbs. 
(n=164) 
%  of total 
number of 
women 
Impregnation 
Аbs. 
(n=68) 
% of number 
of pregnant 
2.1. Without the required 
signs of pathology of 
hemostasis and fibrinolysis 
26 15,8 21 30,9 
2.2. Without the required 
signs of pathology of 
hemostasis and fibrinolysis 
138 84,2 47 69,1 
- including an increase in 
ETP over 1900 nM/min 
and/or with Peack thrombin 
more than 360 nM/l  (2nd 
point of observation) 
50 30,5 19 27,9 
- including those with 
reduced EAAF index less 
than 11% (on the 1st point of 
observation) 
40 24,4 14 20,6 
- including an increase in 
ETP over 1900 nM/min 
and/or  increased Peack 
thrombin more than 360 
nM/l  (2nd point of 
observation) and a decrease 
of the index EAAF less than 
11% (on the 1st point of 
observation) 
48 29,3 14 20,6 
Received treatment against 
diseases of hemostasis, 
including: 
98 59,8 42 61,8 
2.2.1. After heparin 
prophylaxis 
38 23,2 15 22,1 
2.2.2. After IPC course 23 14,0 10 14,7 
2.2.3. When combined IPC 
course with heparin 
prophylaxis 
37 22,6 17 25 
2.2.4. Those in need of 
treatment, but did not 
receive it 
40 24,4 5 7,3 
Table 4. Results of IVF in women of the 2nd (controlled) group in relation to the presence or absence of 
disorders in hemostasis and fibrinolysis 
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of the pulmonary artery thromboembolia (e.g. in the presence of clinically non-evident 
iliofemoral thrombosis) and due to the obtained data on the increased content of t-Pa in 
endotelial vessels of the upper extremities (Pandolfi et al., 1968). That is why we chose 
pneumatic massaging device PM-01 (Russia) to apply a 7-chamber compression brace in the 
upper arm area using the mode of wave compression with the following parameters:   
chambers from 30 to 150 mm. Hg. Art., 45 cycles of compression wave with memory for 30 
minutes to maintain the pressure in the cuff chambers from 5 to 90., the pressure of 
compressed air supplied to the compression performed in a course of 8 sessions (twice a 
week) with 30-minute cuff device to the left or right hand. The starting point of this therapy 
was to reduce EAAF index below 11% measured in a number of patients just prior to IVF 
program (1st point of observation). 
Studies have found that the total number of favorable outcomes of IVF in the 2nd 
(controlled) group was 41.5%, an increase of only 7.1%, compared with those in group 1 
(34.4%; P <0,21) (Table 3 and Table 4). 
However, please note that 40 patients (subgroup 2.2.4) failed our proposed therapy, 
although prescribed by the above criteria. If to sum up the outcome of IVF in all samples in 
the study of women who had indications for treatment but did not receive it for a number of 
reasons (sub 1.2 and 2.2.4; 154 cases) we indicate positive results in 9.1%, whereas in the 
treated patients (subgroup 2.2.1, 2.2.2 and 2.2.3, 98 cases) - in 42.9%, or 4.71 times more 
likely (P<0,000001). 
Effect of treatment produced on the dynamics of hemostasis and fibrinolysis during IVF is 
shown in Table 5. You can see the previous trends in Table 2, but the women in group 2, 
compared to the 1 st group demonstrated lower intensity of thrombin generation and 
improvement of fibrinolysis regardless of the outcome of IVF. 
D-dimer levels in blood plasma has indicated growing trend - the concentration of this 
indicator has been consistently higher regardless of the period of the survey in patients with 
unsuccessful IVF outcome (Tables 2 and 5). However, the value of D-dimer levels was 
within the range of normal variation or slightly exceeded them, hardly matching the 
identified changes parameters under study (Table 6). 
In this regard, we have not put the emphasis on the results of this test upon the following 
analysis. 
Other risk factors of unsuccessful IVF which did not depend on the characteristics of 
hemostatic and fibrinolytic had its effect on IVF success (see Section 2, Table 13, 14), as well as 
the fact of receiving or not receiving therapeutic intervention aimed at reducing the 
thrombogenic potential and increasing fibrinolytic activity of blood. Calculations and 
observations in tables 7-12 demonstrate a better pattern in this regard. In particular, it 
appeared that an approved prescription of low-molecular heparin at high thrombin generation 
at the 2nd stage of the study contributed to the increase in the incidence of pregnancy in 6.4 
times (P<0,0001), isolated IPC course application -in 3.0 times (P<0,007), and the combination 
of IPC course with heparin prophylaxis - in 6.5-times (P<0,0001) (Table 7). 
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Indication At failure in IVF cycle (n=96) At pregnancy (n=68) 
First  
point of 
observation
Second 
point of 
observation
Third  
point of 
observation
First  
point of 
observation
Second 
point of 
observation 
Third  
point of 
observation 
ETP, nM/min 1825,3±96,8* 1922,1±64,7* 1785,4±±89,5 1645,6±54,9 1762,1±79,8 1711,2±84,3 
Peack 
thrombin, 
nM/l 
342,1±26,3** 381,5±25,7** 364,4±24,3** 310,7±27,4 329,1±29,3 326,4±25,7 
t-PA, activity 
un/ml 
0,35±0,14 0,51±0,15 0,48±0,13 0,35±0,15 0,47±0,16 0,44±0,14 
PAI-1, activity 
un/ml 
3,55±1,75 2,64±1,91 2,32±1,58 3,48±2,11 1,95±0,75 1,86±0,57 
EAAF index, 
% 
9,9±4,28 19,3±3,88* 20,6±4,53* 10,0±3,97 24,1±4,39 23,6±4,77 
Clot lysis 
time, min 
15,5±3,65 12,3±3,86 11,4±4,04 13,4±3,85 11,8±3,85 10,1±3,11 
D-dimers, 
ng/ml 
236,4±26,2* 258,6±25,1* 305,6±28,5* 194,7±32,4 233,4±24,5 211,7±28,6 
Table 5. The dynamics of hemostasis and fibrinolysis (M ± SD) in women of second (controlled) group 
(n = 164), t - test 
 
Indication Rank correlation P value 
ETP, nM/min 0,09 0,017 
Peack thrombin, nM/l 0,125 0,002 
t-PA, activity, un/ml 0,118 0,0003 
PAI-1, activity, un/ml 0,124 0,0004 
EAAF index, % 0,107 0,0006 
Clot lysis time, min 0,111 0,0005 
Table 6. Pair correlation between the level of D-dimers (by Spearman) and the study of hemostasis and 
fibrinolysis in different periods of the IVF cycle, regardless of its outcome 
 
Modality In need of treatment, but did 
not receive it (sub-1.2 and 2.2.4; 
n = 154) 
In need of treatment, and 
treated (sub 2.2.1, 2.2.2 and 
2.2.3; n = 98) 
Abs. 
Became 
pregnant
% Abs. 
Became 
pregnant 
% 
1. Heparin Prophylaxis 64 4 6,2 38 15 39,5 
2. IPC course  48 7 14,6 23 10 43,5 
3. Combined effect 42 3 7,1 37 17 45,9 
Table 7. The influence of the methods of correction of hemostatic and fibrinolytic responses to the 
effectiveness of IVF (with data 1 and 2 stage of the research) 
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Criteria such as Absolute Risk Reduction (ARR), Relative Risk (RR), Relative Risk Reduction 
(RRR), Number Needed to Treat (NNT), Confidence Interval (CI) were determined for 
further evaluation of the effectiveness of the treatment (Table 8). 
 
Modality Indication 
ARR NNT OR CI 95% 
(RRR) 
CI 95% 
(OR) 
RRR% 
Heparin Prophylaxis 0,27 3,7 0,22 0,52-0,92 0,07-0,69 31 
IPC Course 0,31 3,2 0,19 0,44-0,94 0,05-0,65 35 
Heparin prophylaxis 
combined with IPC 
course 
0,55 1,8 0,24 0,23-0,60 0,02-0,22 63 
Table 8. The effectiveness of different methods of therapy in women in a cycle of IVF 
 
Indication In need of treatment, but did not receive 
it (subgroup 1.2 и 2.2.4; n=154) 
In need of treatment, and treated 
(subgroup 2.2.1, 2.2.2 и 2.2.3; n=98) 
First  
point of 
observation
Second  
point of 
observation 
Third  
point of 
observation 
First  
point of 
observation
Second 
point of 
observation 
Third  
point of 
observation 
ETP, nM/min 1459,4±85,1 1912,5±108,6** 1872,8±85,1** 1490,6±84,1 1729,8±89,5 1566,4±72,7 
Peack 
thrombin, nM/l 
307,1±31,8 391,2±25,3** 385,4±22,5** 313,1±19,7 362,8±23,1 341,3±25,6 
t-PA, activity, 
un/ml 
0,32±0,15 0,34±0,16 0,33±0,15 0,34±0,12 0,48±0,15 0,49±0,14 
PAI-1, activity, 
un/ml 
3,18±2,32 3,22±1,66 3,26±1,75 3,22±1,71 2,76±1,51 2,68±1,67 
EAAF index, % 10,0±3,2 10,5±4,3** 10,1±4,1** 10,5±3,5 17,3±4,4 18,2±4,2 
Clot lysis time, 
min 
13,1±3,6 14,2±3,9 15,4±3,8** 12,2±4,4 10,1±4,5 9,2±3,4 
Table 9. The dynamics of hemostasis and fibrinolysis (M ± SD) in women in a cycle of IVF when 
indicated for the correction of hemostasis (n = 138), t - test 
The choice was made towards absence of pregnancy after conducted treatment as the 
negative outcome of IVF. The control group included 154 women who had revealed 
violations of blood coagulation and fibrinolysis and did not receive treatment (subgroups 
1.2 and 2.2.4). The intervention group had patients who received one of three therapies 
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aimed at correcting identified violations in the hemostatic system and hypofibrinolysis 
(subgroup 2.2.1, 2.2.2, 2.2.3). It was discovered that all of the treatment reduced the risk of a 
negative outcome of IVF. In particular, in order to prevent one adverse outcome, you need 
to treat 2 women by the combined treatment option (1.8), using the IPC - 3 women (3.2), and 
heparin prophylaxis - 4 women (3.7). The relative risk reduction (RRR) in all cases was 
greater than 25%, which corresponded to clinical effect, and upon combined RRR therapy 
more than 50%, indicated a pronounced clinical effect. 
Evolution of indicators reflecting defects of hemostatic and fibrinolytic reactions in patients 
in need of therapeutic intervention are shown in Table 9. Obviously, undertaken treatment 
has a beneficial effect on the rate of thrombin generation and fibrinolysis, and the index 
EAAF which reflects fibrinolysis-activation ability of the vascular wall indicated the increase 
in 2 times. 
We also made separate calculations of laboratory parameters in women with high thrombin 
generation in need of heparin prophylaxis (Table 10). As a result, it was found that low 
molecular weight heparin with a mid-cycle IVF significantly reduces the generation of 
thrombin. In particular, the background rate nadroparin ETP between the 2nd and 3rd 
observation points decreased by 18.1%, compared to 3.6% in women who did not receive 
anticoagulant. The similar dynamics had Peack thrombin, which decreased, respectively, by 
13.2% and 1.8%. 
 
Indication In need of treatment, but did not receive 
it (subgroup 1.2.1. и 2.2.4.1; n=64) 
At heparin prophylaxis (subgroup 
2.2.1; n=38) 
First  
point of 
observation
Second  
point of 
observation 
Third  
point of 
observation 
First  
point of 
observation
Second 
point of 
observation 
Third 
point of 
observation 
ETP, nM/min 1461,2±81,6 1849,3±89,2 1782,4±93,5** 1489,5±85,5 1861,2±94,4 1524,6±88,9 
Peack 
thrombin, nM/l 
310,1±23,1 382,4±19,5 375,6±25,2** 321,2±22,3 386,3±23,5 335,2±20,2 
t-PA, activity, 
un/ml 
0,30±0,16 0,33±0,15 0,31±0,15 0,33±0,12 0,41±0,16 0,42±0,17 
PAI-1, activity, 
un/ml 
2,40±1,13 2,50±1,22 2,44±1,98 2,84±1,45 3,61±1,75 3,50±1,71 
EAAF index, % 12,5±3,1 13,2±4,2 12,7±3,6 11,62±3,2 11,35±4,2 12,0±3,9 
Clot lysis time, 
min 
9,4±3,0 8,7±3,3 10,1±3,5 8,4±3,7 8,7±2,8 9,7±3,2 
Table 10. The dynamics of hemostasis and fibrinolysis (M ± SD) in the second group of women in the 
presence of indications for heparin prophylaxis (n = 102), t – test 
It should be noted that the indicators of fibrinolytic activity has not changed and remained 
stable without regard to heparin and duration of the study. 
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Indication 
 
In need of treatment, but did not 
receive it (subgroup 1.2.2. и 2.2.4.2; 
n=48) 
IPC Course recipients (subgroup 
2.2.2.2; n=23) 
First point 
of 
observation
Second 
point of 
observation
Third point 
of 
observation
First point 
of 
observation
Second 
point of 
observation 
Third 
point of 
observation 
ETP, nM/min 1534,4±87,2** 1575,7±85,6 1589,6±96,4 1415,1±87,7 1562,3±86,1 1632,3±93,8 
Peack thrombin, 
nM/l 
314,2±30,3* 322,4±28,2 327,7±25,7** 294,5±24,4 322,1±31,1 353,3±25,9 
t-PA, activity, 
un/ml 
0,36±0,14 0,39±0,15 0,37±0,14* 0,35±0,16 0,51±0,15 0,48±0,15 
PAI-1, activity, 
un/ml 
3,98±1,67 4,11±2,32 4,05±2,54* 3,55±1,88 2,64±1,06 2,32±1,32 
EAAF index, % 9,0±3,2 9,5±3,6** 9,1±4,0** 9,9±3,2 19,3±3,4 20,6±4,5 
Clot lysis time, 
min 
13,8±4,3 14,4±4,6* 14,8±3,2** 14,3±4,1 11,4±3,7 9,0±3,3 
Table 11. The dynamics of hemostasis and fibrinolysis (M ± SD) in the second group of women in the 
event of Table readings for IPC course (n = 71), t – test 
 
Indication In need of treatment, but did not 
receive it (subgroup 1.2.3 и 2.2.4.3; 
n=42) 
At heparin prophylaxis  and IPC 
course recipients (subgroup 2.2.3; 
n=37) 
First point 
of 
observation
Second 
point of 
observation
Third point 
of 
observation
First point 
of 
observation
Second 
point of 
observation 
Third 
point of 
observation 
ETP, nM/min 1538,6±78,3 1770,4±85,6 1756,6±95,7** 1566,7±86,3 1764,4±95,7 1542,1±81,3 
Peack thrombin, 
nM/l 
322,3±32,4 379,3±29,1 374,5±31,6** 324,7±27,6 371,2±33,8 335,6±30,7 
t-PA, activity, 
un/ml 
0,37±0,17 0,39±0,15 0,36±0,16 0,31±0,16 0,49±0,15 0,46±0,14 
PAI-1, activity, 
un/ml 
3,64±2,05 4,12±1,77 3,45±1,98 3,02±1,69 2,29±1,14 2,09±0,91 
EAAF index, % 10,2±2,9 9,5±3,1** 10,4±3,3** 10,2±2,6 21,4±4,5 22,0±4,3 
Clot lysis time, 
min 
15,4±3,9 13,2±4,2** 15,7±3,4** 13,8±2,3 10,0±3,8 9,1±3,9 
Table 12. The dynamics of hemostasis and fibrinolysis (M ± SD) in the second group of women when 
indicated for combination therapy (n = 79), t – test 
Similar calculations were performed in women with hypofibrinolysis as well as with the 
combination of low fibrinolytic activity with excessive generation of thrombin (Tables 11 
and 12). It was found that the isolated effects of IPC in women with original, prior to the IVF 
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cycle hypofibrinolysis indicated a sharp increase in EAAF index combined with the decrease 
in CLT. Interestingly, vases compression led to the significant increase of t-PA activity as 
well as to the reduction of PAI-1activity at the end of the IVF cycle. It was also discovered 
that the application of IPC led to increased thrombin generation which Peack thrombin 
factor clearly demonstrated. 
 
Figure 3. The evolution of laboratory parameters of hemostasis and fibrinolysis in women who require 
concomitant therapy, but do not receive it (A) during such therapy (B) 
Combined application of IPC and low molecular weight heparin produced complex 
beneficial effect on hemostasis and fibrinolysis to be in correspondence with the maximum 
increase in the number of IVF successful outcomes (Tables 4, 7, 8 and 12). 
In Fig. 3 the dynamics of the main parameters studied in the course of the treatment for the 
correction of hemostasis and fibrinolysis is highlighted. 
The Means of Progress in Improving the Results of in vitro Fertilization  
Based on the Identification and Correction of the Pathology of Hemostasis 101 
5.2.3. Comparative analysis of the prognostic value of a number of factors contributing to 
the failure of IVF 
This section has recorded and compared the effect of risk factors in the failure of IVF in 1st 
(observation) group and women of (2nd) group. We studied a wide range of adverse 
prognostic factors which are well-known in Reproduction and discussed in this publication: 
markers of thrombogenic risk and blood fibrinolytic activity reduction as well as 
hyperhomocysteinemia, thrombogenic mutations and polymorphisms carriers, presence of 
an inflammatory response (Bates et al., 2008; Coulam & Jeyendran, 2009b; Heit, 2007; 
Qublan & Eid, 2006), "0" blood type negative factor [Canonico et al., 2008; Ohira et al., 2007.)  
Assessing the reasons for the failure of pregnancy in IVF cycles in 163 patients of the 1st 
(observation) group based on the analysis of the odds ratio (OR), 9 out of 27 (33.3% ) factors 
became the most important adverse factors or symptoms to be rated as fairly significant  
(Table 13). Importantly, indicators reflecting increased thrombin generation and inhibition 
of fibrinolytic reactions, respectively, 2nd and 3d entered the adverse factors as well. Hypo 
fibrinolysis factors with high reliability proved to be at the 5th and 6th adverse factors 
ranking. Consequently, in addition to well-known factors listed in Section 2, increased 
ability to thrombosis, in response to the stress estrogen and inhibition of fibrinolytic 
reactions are among the leading causes of failure of IVF. It is interesting to note that such a 
well-known and widely used in clinical practice marker of thrombinemia as high D-dimer 
plasma levels did not vary in frequency of occurrence in impregnate women at all stages of 
observation (OR 0,99; 0,95% CI 0,42-2,31 – 21 rank). 
Carriage of thrombogenic mutations and polymorphisms were identified in the majority of 
our patients (71.2%). By the rare mutations - Factor V Leiden and prothrombin in only 4 
cases (2.4%), we cannot judge the significance of their influence. However, the combination 
of polymorphisms MTGFR and PAI-1 was found in a slightly larger percentage of cases 
with unsuccessful IVF (24.3% vs. 16.0%) to be, however, insignificant. Interestingly, blood 
type “not 0”did not prove to be protrombogen/unfavorable by nature in our observation as 
well as a number of variants of virus infection carriers and the manifestations of 
inflammation (fibrinosis, leukocytosis). 
The number of factors contributing to the failure of pregnancy in IVF changed dramatically 
after exposure to therapeutic correction of hemostasis and fibrinolysis, used in the present 
publication. In accordance with the data in Table 14, traditional reasons for Reproduction 
are among the leaders: early hyperstimulation, male factor, and others. 
Hyperhomocysteinemia (OR 3,45; 0,95% CI 1,16-10,2) became one of the hemostatic reasons 
at the 4th rank to be the result of obvious lack of attention to the problem of metabolic 
methionine in preparation for IVF protocol. The significance level of manifestation of high 
thrombin generation shifted from the 2nd and 3rd rank to 8th and 9th rank whereas EAAF 
index - from 6th to 15th rank to be the further proof of the effectiveness of our methods of 
applied therapeutic intervention. Please, note that the calculations in this table exclude 40 
patients with disorders of hemostasis and fibrinolysis who did not receive treatment for a 
number of reasons (subgroup 2.2.4). 
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Criterion Failure of 
IVF 
(n=107) 
Success of 
IVF (n=56) 
Odds ratio 
(0,95% CI) 
P-value 
Abs. % Abs. % 
 
1. Hyperstimulation  
(early stage) 
22 20,5 0 0 29,7 
(1,76-500) 
< 0,00001 
2. ETP more than 1900 
nM/min (2nd point of 
observation) 
73 68,2 4 7,1 27,9 
(9,33-83,4) 
< 0,00001 
3. Peack thrombin more than 
360 nM/L  
(2nd point of observation) 
74 69,1 5 8,9 22,8 
(8,36-62,5) 
< 0,00001 
4. Oligozoospermia  
(moderate and severe) 
45 42,0 2 3,5 19,5 
(4,53-84,6) 
< 0,00001 
5. Clot lysis time of over 12 
minutes (1st point of 
observation) 
69 64,5 5 8,9 18,5 
(6,81-50,3) 
< 
0,000001 
6. EAAF index less than 11% 
(1st point of observation) 
62 57,9 6 10,7 11,5 
(4,53-29,1) 
0,00005 
7. Defective embryo 23 21,4 3 5,3 4,83 
(1,38-16,9) 
0,011 
8. Insufficient number  
of embryos transferred  
in IVF cycles  
(1-2) 
38 35,5 6 10,7 4,58 
(1,80-11,6) 
0,0007 
9. Mutation FV (G/A, A/A) 3 2,8 0 0 3,78 
(0,19-74,5) 
0,319 
10. Difficult embryo transfer 32 29,9 6 10,7 3,55 
(1,38-9,12) 
0,006 
11. Hypoplasia of the 
endometrium 
11 10,3 3 5,3 2,02 
(0,54-7,57) 
0,383 
12. Unsuccessful IVF attempt 
in history 
20 18,7 6 10,7 1,91 
(0,72-5,08) 
0,260 
13. Homocysteine in blood of 
more than 15 mM/l  
(1st point of observation) 
22 20,5 7 12,5 1,81 
(0,72-4,54) 
0,280 
14. Age (36-40 years) 19 17,7 6 10,7 1,79 
(0,67-4,80) 
0,262 
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Criterion Failure of 
IVF 
(n=107) 
Success of 
IVF (n=56) 
Odds ratio 
(0,95% CI) 
P-value 
Abs. % Abs. % 
 
15. High dose-protocol 35 32,7 12 21,4 1,78 
(0,83-3,79) 
0,148 
16. The combination of 
polymorphisms MTHFR (C/T, 
T/T) and PAI-I  
(5 G/4 G, 4 G/4 G) 
26 24,3 9 16,0 1,67 
(0,72-3,87) 
0,315 
17. Low ovarian reserve 19 17,7 7 12,5 1,51 
(0,59-3,84) 
0,500 
18. Polymorphism of PAI-I (5 
G/4 G, 4 G/4 G) 
42 39,2 20 35,7 1,16 
(0,59-2,27) 
0,735 
19. Cytomegalovirus infection 11 10,3 5 8,9 1,16 
(0,38-3,54) 
> 1,00 
20. Fibrinosis greater than 5.0 
g/l (for 2nd point of 
observation) 
14 13,0 7 12,5 1,05 
(0,39-2,78) 
> 1,00 
21. D-dimer levels over 500 
ng/mL (2nd point of 
observation) 
19 17,7 10 17,8 0,99 
(0,42-2,31) 
> 1,00 
22. Herpes type 1 and 2 35 32,7 21 37,5 0,81 
(0,41-1,59) 
> 1,00 
23. Hypothyroidism 6 5,6 4 7,1 0,77 
(0,20-2,85) 
0,737 
24. Leukocytosis over 
11,0×109/l (1st point of 
observation) 
23 21,5 15 26,8 0,74 
(0,35-1,58) 
> 1,00 
25. Blood group - is not "0" 85 79,4 47 83,9 0,74 
(0,31-1,73) 
0,535 
26. Polymorphism of MTHFR 
(C/T, T/T) 
30 28,0 23 41,0 0,55 
(0,28-1,10) 
0,113 
27. Mutation of FV Leiden 
(G/A) 
1 0,9 1 1,7 0,51 
(0,03-8,45) 
> 1,00 
Table 13. Factors contributing to the failure of pregnancy in IVF cycles in the 1 st. observation group  
(n = 163) 
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Criterion 
Failure of IVF
(n=61) 
Success of 
IVF (n=63) 
Odds ratio 
(0,95% CI) 
P-value 
Abs % Abs % 
 
1. Hyperstimulation (early stage) 12 19,6 0 0 
32,0 
(1,85-555) 
< 0,0001 
2. Oligozoospermia (moderate and 
severe) 
26 42,6 4 6,3 
10,9 
(3,53-34,0) 
0,0002 
3. Insufficient number of embryos 
transferred in IVF cycles (1-2) 
23 37,7 8 12,7 
4,16 
(1,68-10,28) 
0,003 
4. Homocysteine in blood of more 
than 15 nM/l (on the 1st point of 
observation) 
14 22,9 5 7,9 
3,45 
(1,16-10,2) 
0,043 
5. Difficult embryo transfer 18 29,5 7 11,1 
3,34 
(1,28-8,74) 
0,013 
6. Mutation FII (G/A, A/A) 1 1,6 0 0 
3,14 
(0,12-78,8) 
0,491 
7. Defective embryo 17 27,8 8 12,7 
2,65 
(1,04-6,72) 
0,044 
8. Peak thrombin more than 360 
mM/l (for  2nd point of 
observation) 
43 70,4 32 50,8 
2,31 
(1,10-4,84) 
0,028 
9. ETP more than 1900 nM/min 
(2nd point of observation) 
41 67,2 31 49,2 
2,11 
(1,02-4,38) 
0,047 
10. Unsuccessful IVF attempt in 
anamnesis 
11 18,0 6 9,5 
2,09 
(0,72-6,06) 
0,198 
11. D-dimer levels over 500 ng/mL 
(2-nd point of observation) 
13 21,3 8 12,7 
1,86 
(0,71-4,87) 
0,476 
12. Age (36-40 years) 8 13,1 5 7,9 
1,75 
(0,53-5,68) 
0,392 
13. Polymorphism of PAI-I (5 G/4 
G, 4 G/4 G) 
26 42,6 20 31,7 
1,59 
(0,76-3,32) 
0,265 
14. Cytomegalovirus infection 3 4,9 2 3,1 
1,57 
(0,25-9,78) 
1,677 
15. EAAF index less than 11% (1st 
point of observation) 
33 54,0 27 42,8 
1,57 
(0,77-3,19) 
0,280 
16. The combination of 
polymorphisms MTHFR (C/T, T/T) 
and PAI-I (5 G/4 G, 4 G/4 G) 
17 27,8 13 20,6 
1,48 
(0,64-3,40) 
0,706 
17. Fibrinosis greater than 5.0 g/l 
(for the 2nd point of observation) 
8 13,1 6 9,8 
1,43 
(0,46-4,40) 
0,580 
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Criterion 
Failure of IVF
(n=61) 
Success of 
IVF (n=63) 
Odds ratio 
(0,95% CI) 
P-value 
Abs % Abs % 
 
18. High-dose protocol 6 9,8 5 7,9 
1,26 
(0,36-4,38) 
0,760 
19. Blood group - is not "0" 48 78,6 47 74,6 
1,24 
(0,54-2,89) 
0,673 
20. Low ovarian reserve 11 18,0 10 15,8 
1,16 
(0,45-2,98) 
0,813 
21. Clot lysis time of over 12 
minutes (1st point of observation) 
35 57,4 34 53,9 
1,14 
(0,56-2,33) 
0,720 
22. Leukocytosis over 11,0×109/l 
(1st point of observation) 
13 21,3 12 19,0 
1,15 
(0,47-2,77) 
0,824 
23. Hypoplasia of the 
endometrium 
4 6,5 4 6,3 
1,03 
(0,24-4,33) 
> 1,00 
24. Hypothyroidism 4 6,5 4 6,3 
1,03 
(0,24-4,33) 
> 1,00 
25. Herpes type 1 and 2 7 11,4 9 14,3 
0,77 
(0,27-2,23) 
0,790 
26. Polymorphism of MTHFR (C/T, 
T/T) 
12 19,6 25 39,6 
0,37 
(0,16-0,83) 
0,018 
Table 14. Factors contributing to the failure of pregnancy in IVF cycles in the 2nd group (n = 124) 
In our publication we studied a number of women with the known risk factors of IVF 
failures to be less significant regardless of the ongoing correction of hemostasis and hypo 
fibrinolysis. We also record such risk factors as manifestations of inflammatory reaction 
(leukocytosis, fibrinosis) of virus (herpes, cytomegalovirus), the pathology of the thyroid 
gland and a number of others. 
We are particularly interested in the reasons for the failure of IVF which remained relevant 
after therapeutic correction aimed at hemostasis and fibrinolysis. The list is given in Table. 
15. 
As noted earlier (Table 14), in addition to gynecological risk factors, hyperhomocysteinemia, 
and manifestations of excessive thrombin generation became the causes of the failure of IVF. 
Consequently, despite treatment some female patients maintained the trend to intravascular 
coagulation. Earlier, Table 11 demonstrated that isolated course of IPC to treat hypo 
fibrinolysis and other effects led to increased thrombin generation whereas the combination 
of IPC with dalteparin did not lead to such a shift (Table 12). Considering that we used three 
variants of therapeutic intervention our attempt was to determine the frequency of each of 
them under different outcomes of IVF in women with a high ETP in thrombin generation 
test. 
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Criterion Failure of IVF (n=56) Success of IVF 
(n=42) 
P-value 
Abs. % Abs. % 
1. Hyperstimulation (early stage) 10 17,8 0 0 0,004 
2. Oligozoospermia (moderate and 
severe) 
22 39,3 4 9,5 < 0,001 
3. Insufficient number of embryos 
transferred in IVF cycles (1-2) 
18 32,1 5 11,1 0,029 
4. Homocysteine in blood of more 
than 15 nM/l (on the 1st point of 
observation) 
17 30,3 4 9,5 0,039 
5. Difficult embryo transfer 19 33,9 6 14,2 0,035 
6. Defective embryo 18 32,1 5 11,1 0,029 
7. ETP more than 1900 nM/min (2nd 
point of observation) 
39 69,6 17 40,5 0,006 
8. Peak thrombin more than 360 mM/l 
(for  2nd point of observation) 
42 75,0 19 45,2 0,003 
Table 15. Causes for the failure of IVF under conducted therapeutic correction of hemostasis and 
fibrinolysis (n = 98) 
 
 
Figure 4. Analysis of the effectiveness of different therapies with excessive thrombin generation (ETP to 
1900 nM/min in the 2nd point of observation) 
The data in Figure 4 show that the high generation of thrombin and IVF failure is more 
common in the course of isolating IPC and less - in combination therapy. 
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6. Discussion 
To sum up the results we note that excessive thrombin generation and a fibrinolytic 
inhibition fatal reaction (without correction) reduces the effectiveness of IVF and has a 
comparable value compared to the traditional risk factors of reproduction. Thus, our study 
proves a number of recent statements devoted to this problem (Martinez-Zamora et al., 
2011; Meltzer et al., 2010; Nelson & Greer, 2008; Rova et al., 2012; Westerlund et al., 2012). 
However, we have made further progress due to suprathreshold values of laboratory 
parameters which allow to monitor the increased propensity to blood clotting and / or hypo 
fibrinolysis and therefore to identify patients with high risk of IVF failure in order to 
conduct therapeutic correction of disorders . In particular, by the calibrated test of 
thrombography administration of dalteparin was authorized by its indicators (ETP, Peack 
thrombin) to  lead to the effective reduction of thrombin generation as well as the significant 
increase in positive outcomes of IVF (6.4 times). 
We first proposed and tested method and mode of correction hypo fibrinolysis IPC for 
women in a cycle of IVF. It was shown that vases compression in these cases leads to the 
increased activity of t-PA and reduced PAI-1 activity, which is clearly manifested by the 
sharp increase in the calculated EAAF index , accelerated clotlysis time and the increase in 
the number of positive outcomes for assisted reproductive technology in 3 times. However, 
there were no obvious reasons to reduce the dynamic activity of PAI-1 during the course of 
IPC, even though it appeared to be a favorable result of the non-drug therapy. A negative 
consequence of the IPC was the phenomenon increasing the generation of thrombin which 
did not have the prior record. The calculations showed that the IPC in all cases should be 
combined with heparin prophylaxis to obtain the best clinical results. In this publication, 
combining vases compression with prophylactic doses of LMWH (low molecular weight 
heparin) really helped to increase the number of pregnancies in 6.5 times. In our opinion, 
this non-pharmacological approach to correcting hypo fibrinolysis demonstrates great 
potential for use in a number of clinical situations, including pregnancy period. In this 
chapter, we do not include the results of vases compression in women with low fibrinolytic 
activity after IVF in the first 12 weeks of pregnancy. However, the results are encouraging 
and will be published later. 
The leading role of increased thrombin generation and hypo fibrinolysis in negative 
consequences of this reproductive technology has been proved in comparative evaluation of 
the significance of the risk factors of IVF failure. Its value appeared to be comparable with 
such risk factors as ovarian hyperstimulation syndrome, male factor, poor embryo or small 
quantities, or hard to bear embryos. In the meantime, the range of risk factors and their 
significance has changed dramatically after the treatment and correction of disorders of 
hemostasis and fibrinolysis. In particular, the list of relevant factors was reduced 
significantly to hypo fibrinolysis (rated by EAAF index) whereas indicators of excessive 
thrombin generation remained, though in less prominent positions. In addition, risk factors 
such as male factor, insufficient and difficult embryo transfer, as well as their low quality 
became more significant. The publication indicates the important role of 
hyperhomocysteinemia in the failure of IVF. As you know, it refers to the controllable risk 
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factors which can and must be eliminated by recognized medical methods (by taking 
vitamins B6, B12, folic acid) at pre-gravid preparation. 
In our research, we tested only 7 women with rare mutations F V Leiden (1691 G>A) and FII 
(20210 G>A), associated with thrombosis, pregnancy failure and reproductive technologies. 
Therefore, we were unable to prove their relevance to IVF outcomes. A common gene 
polymorphisms MTHFR (C 677> T) and gene PAI 1 (5G>4G) compared with the results of 
Coulam and Jeyendran (2009b) did not prove the significance. 
7. Conclusion 
The research marks the opportunities to progress and improve outcomes of IVF based on 
the identification and correction of the pathology of hemostasis and fibrinolysis. The 
research data may serve as the basis for the development of guidelines and standards which 
allow improving the efficiency of modern reproductive technologies. The marked problem 
requires interdisciplinary approach, joint efforts by obstetricians and hematologists and 
reward by better efficiency of IVF despite the increased cost of diagnosis and treatment of 
disorders of hemostasis and fibrinolysis. 
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